Alkermes to Report Second Quarter Financial Results on July 27, 2022
Alkermes plc (Nasdaq: ALKS) will host a conference call on July 27, 2022 at 8:00 a.m. ET to discuss its second quarter financial results and provide updates on company progress.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will host a conference call on July 27, 2022 at 8:00 a.m. ET to discuss its second quarter financial results and provide updates on company progress. Interested parties can access the webcast via Alkermes' website, with a replay available two hours post-event. Alkermes focuses on developing medicines in neuroscience and oncology, with a portfolio addressing conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder.
Positive
- Company will provide updates on second quarter performance.
- Access to financial results and management insights through a conference call.
Negative
- None.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -1.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, July 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022 to discuss the company's second quarter financial results. Management will also provide an update on the company.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Alex Braun
Investor Relations
+1 781 296 8493
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-second-quarter-financial-results-on-july-27-2022-301590339.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.